237 related articles for article (PubMed ID: 23104476)
1. Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures.
Eimer S; Dugay F; Airiau K; Avril T; Quillien V; Belaud-Rotureau MA; Belloc F
Neuro Oncol; 2012 Dec; 14(12):1441-51. PubMed ID: 23104476
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
Schulte A; Liffers K; Kathagen A; Riethdorf S; Zapf S; Merlo A; Kolbe K; Westphal M; Lamszus K
Neuro Oncol; 2013 Oct; 15(10):1289-301. PubMed ID: 23877316
[TBL] [Abstract][Full Text] [Related]
3. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
Zhang X; Zhang H; Tighiouart M; Lee JE; Shin HJ; Khuri FR; Yang CS; Chen Z'; Shin DM
Int J Cancer; 2008 Sep; 123(5):1005-14. PubMed ID: 18546267
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells.
Liu S; Tang Y; Yuan X; Yuan D; Liu J; Li B; Li Y
Invest New Drugs; 2018 Dec; 36(6):961-969. PubMed ID: 29508248
[TBL] [Abstract][Full Text] [Related]
5. Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition.
Ying M; Wang S; Sang Y; Sun P; Lal B; Goodwin CR; Guerrero-Cazares H; Quinones-Hinojosa A; Laterra J; Xia S
Oncogene; 2011 Aug; 30(31):3454-67. PubMed ID: 21383690
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential.
Stockhausen MT; Kristoffersen K; Stobbe L; Poulsen HS
Cancer Biol Ther; 2014 Feb; 15(2):216-24. PubMed ID: 24525857
[TBL] [Abstract][Full Text] [Related]
7. Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death.
Eimer S; Belaud-Rotureau MA; Airiau K; Jeanneteau M; Laharanne E; Véron N; Vital A; Loiseau H; Merlio JP; Belloc F
Cancer Biol Ther; 2011 Jun; 11(12):1017-27. PubMed ID: 21508666
[TBL] [Abstract][Full Text] [Related]
8. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
Mimeault M; Johansson SL; Vankatraman G; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
Mol Cancer Ther; 2007 Mar; 6(3):967-78. PubMed ID: 17363490
[TBL] [Abstract][Full Text] [Related]
9. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma.
Bar EE; Chaudhry A; Lin A; Fan X; Schreck K; Matsui W; Piccirillo S; Vescovi AL; DiMeco F; Olivi A; Eberhart CG
Stem Cells; 2007 Oct; 25(10):2524-33. PubMed ID: 17628016
[TBL] [Abstract][Full Text] [Related]
10. Crizotinib and erlotinib inhibits growth of c-Met
Goodwin CR; Rath P; Oyinlade O; Lopez H; Mughal S; Xia S; Li Y; Kaur H; Zhou X; Ahmed AK; Ho S; Olivi A; Lal B
Clin Neurol Neurosurg; 2018 Aug; 171():26-33. PubMed ID: 29803091
[TBL] [Abstract][Full Text] [Related]
11. Cyclopamine sensitizes glioblastoma cells to temozolomide treatment through Sonic hedgehog pathway.
Carballo GB; Matias D; Ribeiro JH; Pessoa LS; Arrais-Neto AM; Spohr TCLSE
Life Sci; 2020 Sep; 257():118027. PubMed ID: 32622951
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells.
Karpel-Massler G; Westhoff MA; Zhou S; Nonnenmacher L; Dwucet A; Kast RE; Bachem MG; Wirtz CR; Debatin KM; Halatsch ME
Mol Cancer Ther; 2013 Sep; 12(9):1783-95. PubMed ID: 23832120
[TBL] [Abstract][Full Text] [Related]
13. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
14. Differential role of EGF and BFGF in human GBM-TIC proliferation: relationship to EGFR-tyrosine kinase inhibitor sensibility.
Bajetto A; Porcile C; Pattarozzi A; Scotti L; Aceto A; Daga A; Barbieri F; Florio T
J Biol Regul Homeost Agents; 2013; 27(1):143-54. PubMed ID: 23489694
[TBL] [Abstract][Full Text] [Related]
15. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
[TBL] [Abstract][Full Text] [Related]
16. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.
Ashizawa T; Miyata H; Iizuka A; Komiyama M; Oshita C; Kume A; Nogami M; Yagoto M; Ito I; Oishi T; Watanabe R; Mitsuya K; Matsuno K; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Nakasu Y; Yamaguchi K; Akiyama Y
Int J Oncol; 2013 Jul; 43(1):219-27. PubMed ID: 23612755
[TBL] [Abstract][Full Text] [Related]
17. The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells.
Ramis G; Villalonga-Planells R; Serra-Sitjar M; Brell M; Fernández de Mattos S; Villalonga P
Cell Oncol (Dordr); 2019 Aug; 42(4):521-536. PubMed ID: 30980364
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM.
McKinney A; Lindberg OR; Engler JR; Chen KY; Kumar A; Gong H; Lu KV; Simonds EF; Cloughesy TF; Liau LM; Prados M; Bollen AW; Berger MS; Shieh JTC; James CD; Nicolaides TP; Yong WH; Lai A; Hegi ME; Weiss WA; Phillips JJ
Mol Cancer Ther; 2019 Sep; 18(9):1565-1576. PubMed ID: 31270152
[TBL] [Abstract][Full Text] [Related]
19. Lipid metabolism enzyme ACSVL3 supports glioblastoma stem cell maintenance and tumorigenicity.
Sun P; Xia S; Lal B; Shi X; Yang KS; Watkins PA; Laterra J
BMC Cancer; 2014 Jun; 14():401. PubMed ID: 24893952
[TBL] [Abstract][Full Text] [Related]
20. Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.
Liffers K; Kolbe K; Westphal M; Lamszus K; Schulte A
Target Oncol; 2016 Feb; 11(1):29-40. PubMed ID: 26032687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
